Pulse Biosciences (PLSE) Debt to Equity (2021 - 2023)

Pulse Biosciences (PLSE) recorded quarterly Debt to Equity of -$6.09 in Q1 2023, up 78.93% quarter-over-quarter from -$28.91 in Q4 2022.

Pulse Biosciences (PLSE) Debt to Equity (2021 - 2023) Analysis & Trends

Pulse Biosciences' Debt to Equity history runs 3 years deep, the most recent figure standing at -$6.09 for Q1 2023.

In Q1 2023, Debt to Equity changed N/A year-over-year to -$6.09; the TTM figure through Mar 2023 stood at -$6.09 (changed N/A YoY), while the FY2022 annual figure was -$28.91, changed N/A from the prior year.
Debt to Equity was -$6.09 for Q1 2023 at Pulse Biosciences, up from -$28.91 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of $10.5 in Q3 2022 to a low of -$28.91 in Q4 2022.
Historically, Debt to Equity has averaged -$5.62 across 3 years, with a median of -$2.04 in 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Intuitive Surgical	148.09 Bn	143.69 Bn	1.83 Bn	-
2	Becton Dickinson	41.00 Bn	39.99 Bn	2.15 Bn	0.72
3	Medline	30.38 Bn	36.22 Bn	1.84 Bn	1.12
4	Resmed	28.22 Bn	26.56 Bn	890.98 Mn	0.04
5	West Pharmaceutical Services	23.72 Bn	23.19 Bn	296.40 Mn	0.07
6	Solventum	13.33 Bn	13.33 Bn	1.10 Bn	1.02
7	Cooper Companies	13.12 Bn	12.99 Bn	735.40 Mn	0.30
8	Align Technology	12.86 Bn	11.80 Bn	736.59 Mn	-
9	Baxter International	10.51 Bn	8.47 Bn	891.00 Mn	1.57
10	Pulse Biosciences	1.68 Bn	1.68 Bn	-	-

Download Data